BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brusini R, Varna M, Couvreur P. Advanced nanomedicines for the treatment of inflammatory diseases. Adv Drug Deliv Rev 2020;157:161-78. [PMID: 32697950 DOI: 10.1016/j.addr.2020.07.010] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 17.3] [Reference Citation Analysis]
Number Citing Articles
1 Mariano A, Bigioni I, Ammendola S, Scotto d’Abusco A. The Formulation of the N-Acetylglucosamine as Nanoparticles Increases Its Anti-Inflammatory Activities: An In Vitro Study. Bioengineering 2023;10:343. [DOI: 10.3390/bioengineering10030343] [Reference Citation Analysis]
2 Jaiswal KS, Malka O, Shauloff N, Bersudsky M, Voronov E, Gupta B, Jelinek R. Genistein carbon dots exhibit antioxidant and anti-inflammatory effects in vitro. Colloids Surf B Biointerfaces 2023;223:113173. [PMID: 36724562 DOI: 10.1016/j.colsurfb.2023.113173] [Reference Citation Analysis]
3 Li M, Liu Y, Weigmann B. Biodegradable Polymeric Nanoparticles Loaded with Flavonoids: A Promising Therapy for Inflammatory Bowel Disease. Int J Mol Sci 2023;24. [PMID: 36901885 DOI: 10.3390/ijms24054454] [Reference Citation Analysis]
4 Krishnan N, Peng FX, Mohapatra A, Fang RH, Zhang L. Genetically engineered cellular nanoparticles for biomedical applications. Biomaterials 2023;296:122065. [PMID: 36841215 DOI: 10.1016/j.biomaterials.2023.122065] [Reference Citation Analysis]
5 Yang Y, Hu R, Zheng J, Wang Q, Xu S, Zhou Z, Zhang D, Shen W. Glucocorticoid nanoformulations relieve chronic pelvic pain syndrome and may alleviate depression in mice.. [DOI: 10.21203/rs.3.rs-2423627/v1] [Reference Citation Analysis]
6 Cui H, You Y, Cheng GW, Lan Z, Zou KL, Mai QY, Han YH, Chen H, Zhao YY, Yu GT. Advanced materials and technologies for oral diseases. Sci Technol Adv Mater 2023;24:2156257. [PMID: 36632346 DOI: 10.1080/14686996.2022.2156257] [Reference Citation Analysis]
7 González-Rioja R, Salazar VA, Bastús NG, Puntes V. The development of highly dense highly protected surfactant ionizable lipid RNA loaded nanoparticles. Front Immunol 2023;14:1129296. [PMID: 36923400 DOI: 10.3389/fimmu.2023.1129296] [Reference Citation Analysis]
8 Liao J, Wang H, Liu N, Yang H. Functionally modified halloysite nanotubes for personalized bioapplications. Adv Colloid Interface Sci 2023;311:102812. [PMID: 36427464 DOI: 10.1016/j.cis.2022.102812] [Reference Citation Analysis]
9 Nie Q, Li C, Wang Y, Hu Y, Pu W, Zhang Q, Cai J, Lin Y, Li G, Wang C, Li L, Dou Y, Zhang J. Pathologically triggered in situ aggregation of nanoparticles for inflammation-targeting amplification and therapeutic potentiation. Acta Pharm Sin B 2023;13:390-409. [PMID: 36815041 DOI: 10.1016/j.apsb.2022.07.013] [Reference Citation Analysis]
10 Cereda CMS, Tofoli GR. Nanomedicine Applied to Inflammatory Bowel Diseases. Interdisciplinary Biotechnological Advances 2023. [DOI: 10.1007/978-981-19-8342-9_13] [Reference Citation Analysis]
11 Soltani F, Kamali H, Akhgari A, Ghasemzadeh Rahbardar M, Afrasiabi Garekani H, Nokhodchi A, Sadeghi F. Preparation and Characterization of a Novel Multiparticulate Dosage Form Carrying Budesonide-Loaded Chitosan Nanoparticles to Enhance the Efficiency of Pellets in the Colon. Pharmaceutics 2022;15. [PMID: 36678698 DOI: 10.3390/pharmaceutics15010069] [Reference Citation Analysis]
12 Vitoria Pupo Silvestrini A, Wender Debiasi B, Garcia Praça F, Vitoria Lopes Badra Bentley M. Progress and challenges of lyotropic liquid crystalline nanoparticles for innovative therapies. International Journal of Pharmaceutics 2022;628:122299. [DOI: 10.1016/j.ijpharm.2022.122299] [Reference Citation Analysis]
13 Cytotoxicity of Materials. Biomedical Engineering 2022. [DOI: 10.1002/9783527826674.ch5] [Reference Citation Analysis]
14 Wu J, Ma T, Zhu M, Huang T, Zhang B, Gao J, Lin N. Nanotechnology reinforced neutrophil-based therapeutic strategies for inflammatory diseases therapy. Nano Today 2022;46:101577. [DOI: 10.1016/j.nantod.2022.101577] [Reference Citation Analysis]
15 Mamun AA, Uddin MS, Perveen A, Jha NK, Alghamdi BS, Jeandet P, Zhang HJ, Ashraf GM. Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments. Semin Cancer Biol 2022;86:101-16. [PMID: 36084815 DOI: 10.1016/j.semcancer.2022.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Cai Y, Qi J, Lu Y, He H, Wu W. The in vivo fate of polymeric micelles. Adv Drug Deliv Rev 2022;:114463. [PMID: 35905947 DOI: 10.1016/j.addr.2022.114463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Murphy EP, Crean D. NR4A1-3 nuclear receptor activity and immune cell dysregulation in rheumatic diseases. Front Med 2022;9. [DOI: 10.3389/fmed.2022.874182] [Reference Citation Analysis]
18 Brannon ER, Guevara MV, Pacifici NJ, Lee JK, Lewis JS, Eniola-adefeso O. Polymeric particle-based therapies for acute inflammatory diseases. Nat Rev Mater. [DOI: 10.1038/s41578-022-00458-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Liu Z, Lian W, Long Q, Cheng R, Torrieri G, Zhang B, Koivuniemi A, Mahmoudzadeh M, Bunker A, Gao H, He H, Chen Y, Hirvonen J, Zhou R, Zhao Q, Ye X, Deng X, Santos HA. Promoting Cardiac Repair through Simple Engineering of Nanoparticles with Exclusive Targeting Capability toward Myocardial Reperfusion Injury by Thermal Resistant Microfluidic Platform. Adv Funct Materials. [DOI: 10.1002/adfm.202204666] [Reference Citation Analysis]
20 Zoulikha M, Huang F, Wu Z, He W. COVID-19 inflammation and implications in drug delivery. J Control Release 2022;346:260-74. [PMID: 35469984 DOI: 10.1016/j.jconrel.2022.04.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Madamsetty VS, Mohammadinejad R, Uzieliene I, Nabavi N, Dehshahri A, García-Couce J, Tavakol S, Moghassemi S, Dadashzadeh A, Makvandi P, Pardakhty A, Aghaei Afshar A, Seyfoddin A. Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems. ACS Biomater Sci Eng 2022;8:1763-90. [PMID: 35439408 DOI: 10.1021/acsbiomaterials.2c00026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Adeyemi JO, Oriola AO, Onwudiwe DC, Oyedeji AO. Plant Extracts Mediated Metal-Based Nanoparticles: Synthesis and Biological Applications. Biomolecules 2022;12:627. [DOI: 10.3390/biom12050627] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
23 Kumar M, Jha A, Bharti K, Parmar G, Mishra B. Advances in lipid-based pulmonary nanomedicine for the management of inflammatory lung disorders. Nanomedicine (Lond) 2022. [PMID: 35451334 DOI: 10.2217/nnm-2021-0389] [Reference Citation Analysis]
24 Crintea A, Dutu AG, Sovrea A, Constantin AM, Samasca G, Masalar AL, Ifju B, Linga E, Neamti L, Tranca RA, Fekete Z, Silaghi CN, Craciun AM. Nanocarriers for Drug Delivery: An Overview with Emphasis on Vitamin D and K Transportation. Nanomaterials (Basel) 2022;12:1376. [PMID: 35458084 DOI: 10.3390/nano12081376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zheng J, Hu R, Yang Y, Wang Y, Wang Q, Xu S, Yao P, Liu Z, Zhou J, Yang J, Bao Y, Zhang D, Shen W, Zhou Z. Antibiotic-loaded reactive oxygen species-responsive nanomedicine for effective management of chronic bacterial prostatitis. Acta Biomater 2022;143:471-86. [PMID: 35259516 DOI: 10.1016/j.actbio.2022.02.044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Praveen TK, Gangadharappa HV, Abu Lila AS, Moin A, Mehmood K, Krishna KL, Hussain T, Alafanan A, Shakil S, Rizvi SMD. Inflammation targeted nanomedicines: patents and applications in cancer therapy. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Manners N, Priya V, Mehata AK, Rawat M, Mohan S, Makeen HA, Albratty M, Albarrati A, Meraya AM, Muthu MS. Theranostic Nanomedicines for the Treatment of Cardiovascular and Related Diseases: Current Strategies and Future Perspectives. Pharmaceuticals 2022;15:441. [DOI: 10.3390/ph15040441] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
28 Difonzo M, Fliedel L, Mignet N, Andrieux K, Alhareth K. How Could Nanomedicine Improve the Safety of Contrast Agents for MRI during Pregnancy? Sci 2022;4:11. [DOI: 10.3390/sci4010011] [Reference Citation Analysis]
29 González-ballesteros N, Diego-gonzález L, Lastra-valdor M, Grimaldi M, Cavazza A, Bigi F, Rodríguez-argüelles MC, Simón-vázquez R. Immunomodulatory and Antitumoral Activity of Gold Nanoparticles Synthesized by Red Algae Aqueous Extracts. Marine Drugs 2022;20:182. [DOI: 10.3390/md20030182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Jogpal V, Sanduja M, Dutt R, Garg V, Tinku. Advancement of nanomedicines in chronic inflammatory disorders. Inflammopharmacology 2022. [PMID: 35217901 DOI: 10.1007/s10787-022-00927-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Miao R, Jin F, Wang Z, Lu W, Liu J, Li X, Zhang RX. Oral delivery of decanoic acid conjugated plant protein shell incorporating hybrid nanosystem leverage intestinal absorption of polyphenols. Biomaterials 2022;281:121373. [DOI: 10.1016/j.biomaterials.2022.121373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Moharana M, Sahu SN, Pattanayak SK, Khan F. A comprehensive study toward the treatment of inflammatory diseases through nanoparticles. Advanced Nanomaterials for Point of Care Diagnosis and Therapy 2022. [DOI: 10.1016/b978-0-323-85725-3.00007-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Deore MS, Mehta H, Naqvi S. Role of Nanomedicine in Treating Ischemic Stroke. Regenerative Therapies in Ischemic Stroke Recovery 2022. [DOI: 10.1007/978-981-16-8562-0_11] [Reference Citation Analysis]
34 Han HS, Koo SY, Choi KY. Emerging nanoformulation strategies for phytocompounds and applications from drug delivery to phototherapy to imaging. Bioactive Materials 2021. [DOI: 10.1016/j.bioactmat.2021.11.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Roată C, Iacob Ș, Morărașu Ș, Livadaru C, Tudorancea I, Luncă S, Dimofte M. Collagen-Binding Nanoparticles: A Scoping Review of Methods and Outcomes. Crystals 2021;11:1396. [DOI: 10.3390/cryst11111396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Li S, Wang L, Gu Y, Lin L, Zhang M, Jin M, Mao C, Zhou J, Zhang W, Huang X, Corbo C, Tao W, Lu E, Liu J. Biomimetic immunomodulation by crosstalk with nanoparticulate regulatory T cells. Matter 2021;4:3621-45. [DOI: 10.1016/j.matt.2021.08.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
37 Bentley ER, Little SR. Local delivery strategies to restore immune homeostasis in the context of inflammation. Adv Drug Deliv Rev 2021;178:113971. [PMID: 34530013 DOI: 10.1016/j.addr.2021.113971] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
38 Huang Y, Wang X, Zhou D, Zhou W, Dai F, Lin H. Macrophages in heterotopic ossification: from mechanisms to therapy. NPJ Regen Med 2021;6:70. [PMID: 34702860 DOI: 10.1038/s41536-021-00178-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
39 Qiao Q, Liu X, Yang T, Cui K, Kong L, Yang C, Zhang Z. Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design. Acta Pharm Sin B 2021;11:3060-91. [PMID: 33977080 DOI: 10.1016/j.apsb.2021.04.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
40 Zu M, Ma Y, Cannup B, Xie D, Jung Y, Zhang J, Yang C, Gao F, Merlin D, Xiao B. Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases. Adv Drug Deliv Rev 2021;176:113887. [PMID: 34314785 DOI: 10.1016/j.addr.2021.113887] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 12.5] [Reference Citation Analysis]
41 Oshi MA, Haider A, Siddique MI, Zeb A, Jamal SB, Khalil AAK, Naeem M. Nanomaterials for chronic inflammatory diseases: the current status and future prospects. Appl Nanosci 2021. [DOI: 10.1007/s13204-021-02019-8] [Reference Citation Analysis]
42 Gao C, Cheng Q, Li J, Chen J, Wang Q, Wei J, Huang Q, Lee SMY, Gu D, Wang R. Supramolecular Macrophage‐Liposome Marriage for Cell‐Hitchhiking Delivery and Immunotherapy of Acute Pneumonia and Melanoma. Adv Funct Mater 2021;31:2102440. [DOI: 10.1002/adfm.202102440] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
43 Zhang G, Ma L, Bai L, Li M, Guo T, Tian B, He Z, Fu Q. Inflammatory microenvironment-targeted nanotherapies. J Control Release 2021;334:114-26. [PMID: 33887284 DOI: 10.1016/j.jconrel.2021.04.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
44 Biswasroy P, Pradhan D, Kar B, Ghosh G, Rath G. Recent Advancement in Topical Nanocarriers for the Treatment of Psoriasis. AAPS PharmSciTech 2021;22:164. [PMID: 34041632 DOI: 10.1208/s12249-021-02057-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
45 Paus C, van der Voort R, Cambi A. Nanomedicine in cancer therapy: promises and hurdles of polymeric nanoparticles. Exploration of Medicine. [DOI: 10.37349/emed.2021.00040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
46 Couvreur P. (Poly-cyanoacrylate) nanomedicines for cancer and beyond: Lessons learned. J Control Release 2021;334:318-26. [PMID: 33915223 DOI: 10.1016/j.jconrel.2021.04.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
47 Peng Y, Ma Y, Bao Y, Liu Z, Chen L, Dai F, Li Z. Electrospun PLGA/SF/artemisinin composite nanofibrous membranes for wound dressing. Int J Biol Macromol 2021;183:68-78. [PMID: 33892031 DOI: 10.1016/j.ijbiomac.2021.04.021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
48 Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z, He W. Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B 2021;11:941-60. [PMID: 33996408 DOI: 10.1016/j.apsb.2020.12.018] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 19.0] [Reference Citation Analysis]
49 Talamini L, Matsuura E, De Cola L, Muller S. Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases. Cells 2021;10:707. [PMID: 33806746 DOI: 10.3390/cells10030707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Sun L, Fan M, Huang D, Li B, Xu R, Gao F, Chen Y. Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis. Biomaterials 2021;271:120761. [PMID: 33774524 DOI: 10.1016/j.biomaterials.2021.120761] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 14.0] [Reference Citation Analysis]
51 Ashford MB, England RM, Akhtar N. Highway to Success—Developing Advanced Polymer Therapeutics. Adv Therap 2021;4:2000285. [DOI: 10.1002/adtp.202000285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
52 Gao C, Yu S, Zhang X, Dang Y, Han DD, Liu X, Han J, Hui M. Dual Functional Eudragit® S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis. Int J Nanomedicine 2021;16:1405-22. [PMID: 33658780 DOI: 10.2147/IJN.S291090] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
53 Perrelli A, Fatehbasharzad P, Benedetti V, Ferraris C, Fontanella M, De Luca E, Moglianetti M, Battaglia L, Retta SF. Towards precision nanomedicine for cerebrovascular diseases with emphasis on Cerebral Cavernous Malformation (CCM). Expert Opin Drug Deliv 2021;18:849-76. [PMID: 33406376 DOI: 10.1080/17425247.2021.1873273] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
54 Ribeiro SB, de Araújo AA, Oliveira MMB, Santos Silva AMD, da Silva-Júnior AA, Guerra GCB, Brito GAC, Leitão RFC, Araújo Júnior RF, Garcia VB, Vasconcelos RC, de Medeiros CACX. Effect of Dexamethasone-Loaded PLGA Nanoparticles on Oral Mucositis Induced by 5-Fluorouracil. Pharmaceutics 2021;13:53. [PMID: 33406583 DOI: 10.3390/pharmaceutics13010053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
55 Fernández-Álvarez F, Caro C, García-García G, García-Martín ML, Arias JL. Engineering of stealth (maghemite/PLGA)/chitosan (core/shell)/shell nanocomposites with potential applications for combined MRI and hyperthermia against cancer. J Mater Chem B 2021;9:4963-80. [PMID: 34114575 DOI: 10.1039/d1tb00354b] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
56 Yin Dou, Chenwen Li, Lanlan Li, Jiawei Guo, Jianxiang Zhang. Bioresponsive drug delivery systems for the treatment of inflammatory diseases. J Control Release 2020;327. [PMID: 32911014 DOI: 10.1016/j.jconrel.2020.09.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 47] [Article Influence: 22.3] [Reference Citation Analysis]
57 Sadeghi-Ghadi Z, Ebrahimnejad P, Talebpour Amiri F, Nokhodchi A. Improved oral delivery of quercetin with hyaluronic acid containing niosomes as a promising formulation. J Drug Target 2021;29:225-34. [PMID: 32997536 DOI: 10.1080/1061186X.2020.1830408] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]